ABSTRACT
INTRODUCTION
With the increasing popularity of dental implants, the lack of sufficient amount of jaw bone has become a significant limitation. To overcome this constraint, researchers started focusing on bone regeneration in the context of dental implant surgery [1] [2] [3] [4] . Over the past two decades, hydroxyapatite has proven to be an excellent bone substitute for its biocompatibility and space maintainability [5, 6] . More recently, commercialization of hydroxyapatite bone substitute has been made possible, with most of the products being available as granular particles or blocks [7] .
In clinical practice, however, these products have shown poor operational performance, for some clinicians opt to mix hydroxyapatite with venous blood or plateletrich plasma [8, 9] or use fiber-type hydroxyapatite. However, most of the initial attempts for obtaining pure hydroxyapatite fiber (HAF) have failed, as the adhesive or coating materials used drastically reduced its purity [10, 11] . In recent years, pure HAF has been developed successfully, and its capacity to induce bone formation has been demonstrated [12, 13] . Besides its effects on bone growth, HAF is also expected to serve as a carrier by holding substances within its three-dimensional structure and slowly releasing them-just like a drug-delivery system [14] .
Growth factors, such as platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), fibroblast growth factor (FGF), and bone morphogenetic protein (BMP)-2, have been reported to promote bone regeneration [15] [16] [17] [18] . However, 2 issues limit their use in clinical practice: most of these growth factors are xenogeneic, and they are expensive. As an alternative, statins-widely known as competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase that lower cholesterol levels [19] -have also been shown to increase BMP-2-induced bone formation [20, 21] . Our previous study using simvastatin yielded similar results [22] . This effect appears to depend on the concentration of the drug, but high concentrations of simvastatin are unwanted because they provoke inflammation to the mandibular bone [23] .
The aims of the present study were 1) to investigate the carrier properties of HAF by measuring the release of simvastatin from HAF/simvastatin compound materials; and 2) to measure bone regeneration induced by different blends of simvastatin combined with HAF.
MATERIALS AND METHODS

Sample Preparation
We used a previously described HAF compound (Fujii S., United State Patent No. 4,659,617) that was 5 -15 μm in diameter [12, 13] . Energy dispersive X-ray analysis confirmed its purity; its three-dimensional structure is shown in Figure 1 . Simvastatin (Ohara Pharmaceutical Co. Ltd., Koka, Shiga, Japan) was dissolved in ethanol. The solution was dropped onto HAF under sterile conditions, and then allowed to dry completely in a laminar flow hood for 24 h. We prepared 4 groups of samples, each containing 40 mg HAF and 0 mg, 0.15 mg, 0.45 mg, and 0.75 mg simvastatin, respectively.
Measurement of Simvastatin Release
The release of simvastatin from HAF was measured by using an ultraviolet-visible spectrophotometer (Nanodrop ND-1000; NanoDrop Technologies, Wilmington, DE, USA). The Nanodrop was calibrated using 8 standards of simvastatin solution at ambient temperature. The absorbance was measured at 238 nm, and a standard curve for calculation of simvastatin concentrations was generated from the absorbance values. The samples were placed in 1 ml of 0.1 M Tris buffer solution (pH 7.4), and shaken on a Taitec Personal 11 Shaker (Taitec Corp., Tokyo, Japan) at 100 rpm at ambient temperature. The amount of simvastatin released into the buffer was scored every 24 h for 10 days. The cumulative concentration was calculated by using the previously determined stan- dard curve.
Surgical Procedures for the Rabbit Cranial Chamber Model
The animal experimental protocol was approved by the Institutional Committee of Animal Care and Use at Tokyo Medical and Dental University. Twenty Japanese white rabbits weighing 2.5 -3.0 kg were used. The animals were systemically anesthetized with an intramuscular injection of ketamine (50 mg/kg Ketalar; Sankyo, Tokyo, Japan) and thiopental sodium (25 mg/kg Rabonal; Tanabe, Tokyo, Japan). The surgical area was shaved and prepared aseptically with povidone-iodine (Isodine Surgical Scrub; Meiji, Tokyo, Japan) for surgery. Before surgery, 1.8 ml of a local anesthetic (2% xylocaine: epinephrine 1:80,000; Dentsply Sankin, Tokyo, Japan) was injected into the surgical site. Skin incision and dissection were carried out coronally, and periosteum incision and dissection were performed sagittally between the parietal and the frontal bone. After the periosteum was elevated, polytetrafluoroethylene chambers (hollow cylinders of 5.0 mm in diameter and 3.0 mm in height with an outer brim) were fixed with stainless steel screws (FKG Dentaire, Chaux-de-Fonds, Switzerland) to the parietal bone on the right and left sides. The chambers were filled with samples, which were selected randomly ( Figure 2) . The skin flaps were sutured with 4-0 nylon. During the observation period, all animals were given water and a standard feed ad libitum. Animals were sacrificed at 4 weeks or 8 weeks with a lethal dose of thiopental sodium. The entire cranial bone was harvested and fixed for 10 days in neutral 10% formalin.
Micro-Computed Tomography (Micro-CT) Analysis
The samples were scanned by a micro-CT scanner
(SMX-90CT; Shimadzu Science East Corporation, Tokyo, Japan) with a voxel size of 60 μm/pixel, and quantified by using the Tri/3D-Bon software (Ratoc System Engineering Co. Ltd., Tokyo, Japan). The percentage of new bone volume occupying the total chamber volume was determined.
Histological Processing
After micro-CT analysis, the specimens were dehydrated in ascending grades of ethanol, following infiltration, and then embedded in methacrylate-based resin (Technovit 7200 VLC; Heraeus Kulzer, Wehrheim, Germany). The sections were cut and ground to a thickness of about 100 m. The sections were finally stained with 0.1% toluidine blue. Histological observation was performed under a light microscope. The percentage of new bone in total chamber volume was measured with an image software (Photoshop CS6 extended, Adobe Systems complex, California, USA). The measurement was performed by a co-author.
Statistical Analysis
For statistical analysis, the data were tested by oneway analysis of variance (ANOVA). The data were further analyzed by Fisher's least significant difference test and Bonferroni multiple comparison test. All statistical analyses were performed using a commercial computer program (SPSS v. 11.5; SPSS Inc., Chicago, IL, USA). A value of p < 0.05 was considered to be statistically significant.
RESULTS
Simvastatin Was Released from HAF in 2 Phases
Approximately 10% of absorbed simvastatin was released after 24 h. After this initial burst release, gradual and stable release of simvastatin was observed for 10 days (Figure 3) . A similar release pattern was observed regardless of the initial concentration of simvastatin.
Micro-CT Analysis
Four weeks after surgical intervention, the percentage of new bone in the total chamber volume was 22.36% ± 4.98%, 21.30% ± 7.70%, 41.58% ± 6.03%, and 26.32% ± 6.19% in the groups treated with different simvastatin/HAF ratios (0/40 mg, 0. 
Histology
The main histological findings are presented in Figures 5-8 . Four weeks after surgical intervention, the inner space of HAF-filled chambers was maintained clear in each group (Figure 5) , i.e., there was no connective tissue invagination from the top of the chambers. However, some blood cells were observed. We also noted that the HAF fragment was oriented in different directions from sample to sample. The newly formed bone was found towards the bottom of the chamber, close to the host bone, in both control and simvastatin/HAF 0.15/40 mg groups. On the other hand, in the 0.45/40 mg group, the newly formed bone was found approximately at middle-height level between top of the chamber and host bone; in the 0.75/40 mg group, the newly formed bone progressed up to approximately one-quarter of the total height of the chamber. The new bone connected with the host bone Figure 4 . Micro-CT analysis, 4 weeks: The percentage of new bone in the total chamber volume was 22.36% ± 4.98%, 21.30% ± 7.70%, 41.58% ± 6.03%, and 26.32% ± 6.19% in the groups treated with different simvastatin/HAF ratios. 8 weeks: The volume was 20.22% ± 5.53%, 11.72% ± 3.53%, 42.14% ± 4.43%, and 31.22% ± 8.58%, respectively (n = 5, * p < 0.05). nective tissue (Figure 7) . However, the space between the HAF fragment-which was oriented in different directions from sample to sample-and the new bone was filled with blood cells and fat cells. In contrast to the samples dissected at 4 weeks after surgery, samples dissected at 8 weeks after surgery clearly showed the trabecular bone structure. Moreover, newly formed bone stained more similarly to host bone. The amount and relative position of new bone in the chambers were similar to those found at 4 weeks. The newly formed bone bridged with the host bone and showed a "mothand grew toward the HAF. It was possible to differentiate new bone from host bone based on differences in staining and on morphological appearance, i.e., new bone presented a "moth-eaten-like appearance" (Figure 6) . Eight weeks after surgical intervention, the inner space of the chambers was still clear and free of con-eaten-like appearance" (Figure 8) . Inflammation was not observed at any of the 2 time points analyzed.
The results of histological measurement were similar to the micro-CT's (Figure 9) . For four weeks, the percentage of new bone in the total chamber volume was 22.30% ± 9.52%, 21.36% ± 5.24%, 41.38% ± 11.18%, and 19.51% 
DISCUSSION
In this study, we confirmed the role of simvastatin in bone formation and regeneration. Simvastatin and other statins have been widely used for lowering serum levels of cholesterol in hypercholesterolemia, hyperlipidemia, and arteriosclerosis [19] . In recent years, several studies have shown that statins enhance BMP-2 and vascular endothelial growth factor (VEGF) gene expression in osteoblasts, suggesting their bone-promoting effect [21, 24, 25] . Animal studies involving systemic or local administration of statins have also yielded positive results [23, [26] [27] [28] . However, systemic administration of statins for bone formation requires a much more higher dose than for lowering cholesterol, and safety has not yet been clearly reported [29, 30] . On the other hand, local administration can be performed with smaller doses, but it requires multiple or continuous injections [31] . In response to this drawback, local application of low-dose statin with a slow-release drug-delivery system has been suggested [32, 33] . In this study, we showed that HAF can serve as a substance carrier by demonstrating the stable release of simvastatin from HAF/simvastatin compound materials. This is in agreement with the report by Oda et al. [14] , who suggested HAF as a potential component of a drug-delivery system based on its biocompatibility, biode-gradability, and cotton-like fibrous 3D structure. Importantly, the effects of HAF in bone formation have been demonstrated by using the rabbit cranium chamber model [12] and the post-extraction tooth socket model [13] . Kimura et al. [12] demonstrated that the combination of HAF with autogenous bone was effective in vertical bone augmentation, and Machida et al. [13] indicated that HAF could not only allow but also promote bone healing of the socket after tooth extraction. Therefore, we used simvastatin as growth-factor-like substance and HAF as scaffold in the present study. Here, an in vitro study showed that simvastatin is released gradually over time after an initial burst release from HAF. This release pattern was considered to be similar to that observed in several studies using other biomaterials, including alphatricalcium phosphate (TCP) [34] , collagen sponge [35] , electrospun fiber material [36] , as the drug-delivery system. The bone-promoting effect of simvastatin correlated well with concentration [37] ; thus, the initial burst release was thought to be a critical phase [34] . Addition- Figure 9 . Histological analysis, 4 weeks: The percentage of new bone in the total chamber volume was 22.30% ± 9.52%, 21.36% ± 5.24%, 41.38% ± 11.18%, and 19.51% ± 3.80% in the groups treated with different simvastatin/HAF ratios. 8 weeks: The volume was 22.45% ± 4.04%, 18.21% ± 5.44%, 41.11% ± 11.79%, and 33.24% ± 2.58%, respectively (n = 5, * p < 0.05).
ally the release pattern always showed a constant curve regardless of concentration, indicating that the correlation coefficient of the release volume might be similar. Therefore, the release of simvastatin was considered to be adjusted by altering the amount of simvastatin added initially.
In the animal experiment, we used the rabbit cranial chamber model. Traditionally, the cranial bone defect model [38] , tibia bone defect model [39] , and post-extraction tooth socket model [40] were used to evaluate new bone formation in vivo. However, these models are not always rigorous enough to identify and evaluate the extent of new bone formation, since in these models bone can heal without pharmacological treatment [41] . Instead, the rabbit cranial chamber model offers a good model for new bone formation; in this model, the amount of new bone can be evaluated conveniently since the size of the chamber is constant. In this study, 40 mg HAF were used. This dose had been demonstrated as the optimal dose for bone formation by Fujii et al. (2013) with using the same animal model.
To quantify the amount of newly formed bone, we used micro-CT analysis and histological measurement. Both showed the similar results, that suggested the validity of estimation method. We observed that 0.45 mg simvastatin induced significantly greater bone formation than lower amounts added to HAF at 4 weeks and 8 weeks after surgery, respectively. This strongly suggests that the bone-promoting effect of simvastatin is dosedependent, with 0.45/40 mg simvastatin/HAF being the most effective combination. In previous studies, Nyan et al. [37] applied 0.1 mg simvastatin with 14 mg alpha-TCP to rat calvarial defects, and Pradeep et al. [32] performed a randomized trial to treat chronic periodontitis with approximately 1.2% simvastatin solution. Both studies showed positive results with simvastatin concentrations that were similar to the most effective dose of our study (0.45/40 mg).
Histological observations supported the above-mentioned findings. In addition, staining intensity and morphology of new bone at 8 weeks were more similar to host bone than at 4 weeks, which suggested the advanced maturation of new bone within 8 weeks. However, at an earlier time point, similar staining intensity and morphology of new bone were observed regardless of the different concentrations of simvastatin, which indicated that simvastatin could stimulate bone formation but not bone maturation. In agreement with our observations, Lee et al. [42] suggested that it was possible for simvastatin to stimulate bone formation but not bone maturation, and that much of the newly formed bone by simvastatin was resorbed in the long term.
Some researchers reported that a high dose of simvastatin could evoke inflammatory response in animal studies [23, 37] , but no inflammation was found in the present study. This indicates that our highest dose (0.75 mg) might not have been high enough to cause inflammatory reaction. Another curious effect of simvastatin is ectopic bone formation [14] . In our study model, in which the chamber was covered by periosteum, some mesenchymal cells could have had the chance to enter from the top of the chamber. However, there was no new bone formed at the top level of the chamber. Instead, newly formed bone connected with the host bone tightly.
In conclusion, this study revealed that HAF has the potential to be used as a carrier for simvastatin. Combinations of HAF and simvastatin stimulated new bone formation in a dose-dependent manner. Under our experimental conditions, we found 0.45/40 mg simvastatin/ HAF to be the optimal combination dose for bone formation.
CONCLUSION
In conclusion, this study revealed that HAF has the potential to be used as a carrier for simvastatin. Combinations of HAF and simvastatin stimulated new bone formation in a dose-dependent manner. Under our experimental conditions, we found out that 0.45/40 mg simvastatin/HAF is the optimal combination dose for bone formation.
